Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-β gene vector and dendritic cells

Cancer Gene Therapy

Volumn 10, Issue 7, 2003, Pages 549-558

  Nakahara, Norimoto ^a   Pollack, Ian F ^b   Storkus, Walter J ^b   Wakabayashi, Toshihiko ^c   Yoshida, Jun ^c   Okada, Hideho ^b  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cytotoxic T cells; Dendritic cells; Gene therapy; Gliomas; Interferon

Indexed keywords

COMPLEMENTARY DNA; LIPOSOME; RECOMBINANT BETA INTERFERON;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL ACTIVITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA VECTOR; GENETIC TRANSFECTION; GLIOMA; GROWTH INHIBITION; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; CELLS, CULTURED; COCULTURE TECHNIQUES; DENDRITIC CELLS; DRUG CARRIERS; GENE THERAPY; GENETIC VECTORS; GLIOMA; INTERFERON-BETA; LIPOSOMES; MICE; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0038494559     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700598     Document Type: Article

References (69)

1. De Maeyer E, De Maeyer-Guignard J, Thomson A, eds. Interferons. In: The Cytokine Handbook, 3rd edn. Vol. 18, 1998:491-516. Academic Press, New York.
2. Johns TG, Mackay IR, Callister KA, et al. Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon beta. J Natl Cancer Inst. 1992;84:1185-1190.
3. Buckner JC, Schomberg PJ, McGinnis WL, et al. A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma. Cancer. 2001;92:420-433.
4. Wakabayashi T, Yoshida J, Mizuno M, et al. Effectiveness of interferon-beta, ACNU, and radiation therapy in pediatric patients with brainstem glioma. Neurol Med Chir (Tokyo). 1992;32:942-946.
5. Yoshida J, Kajita Y, Wakabayashi T, et al. Long-term follow-up results of 175 patients with malignant glioma: importance of radical tumour resection and postoperative adjuvant therapy with interferon, ACNU and radiation. Acta Neurochir (Wien). 1994;127:55-59.
6. Wakabayashi T, Hatano N, Kajita Y, et al. Initial and maintenance combination treatment with interferon-beta, MCNU (Ranimustine), and radiotherapy for patients with previously untreated malignant glioma. J Neurooncol. 2000;49:57-62.
7. Yoshida J, Mizuno M, Yagi K. Cytotoxicity of human beta-interferon produced in human glioma cells transfected with its gene by means of liposomes. Biochem Int. 1992;28:1055-1061.
8. Mizuno M, Yoshida J, Sugita K, et al. Growth inhibition of glioma cells transfected with the human beta-interferon gene by liposomes coupled with a monoclonal antibody. Cancer Res. 1990;50:7826-7829.
9. Natsume A, Mizuno M, Ryuke Y, et al. Antitumor effect and cellular immunity activation by murine interferon-beta gene transfer against intracerebral glioma in mouse. Gene Ther. 1999;6:1626-1633.
10. Natsume A, Tsujimura K, Mizuno M, et al. IFN-beta gene therapy induces systemic antitumor immunity against malignant glioma. J Neurooncol. 2000;47:117-124.
11. Mizuno M, Yoshida J. Effect of human interferon beta gene transfer upon human glioma, transplanted into nude mouse brain, involves induced natural killer cells. Cancer Immunol Immunother. 1998;47:227-232.
12. Tjuvajev J, Gansbacher B, Desai R, et al. RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma. Cancer Res. 1995;55:1902-1910.
13. Sampson JH, Ashley DM, Archer GE, et al. Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion. Neurosurg. 1997;41:1365-1372.
14. Santini SM, Lapenta C, Logozzi M, et al. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med. 2000;191:1777-1788.
15. Liu S, Yu Y, Zhang M, et al. The involvement of TNF-alpha-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-beta-stimulated human dendritic cells to tumor cells. J Immunol. 2001;166:5407-5415.
16. Lotze MT. Getting to the source: dendritic cells as therapeutic reagents for the treatment of cancer patients (Editorial). Ann Surg. 1997;226:1-5.
17. Lanzavecchia A, Sallusto F. Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells. Science. 2000;290:92-97.
18. Nestle FO, Banchereau J, Hart D. Dendritic cells: on the move from bench to bedside. Nat Med. 2001;7:761-765.
19. Luft T, Pang KC, Thomas E, et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol. 1998;161:1947-1953.
20. Paquette RL, Hsu NC, Kiertscher SM, et al. Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J Leukocyte Biol. 1998;64:358-367.
21. Parlato S, Santini SM, Lapenta C, et al. Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood. 2001;98:3022-3029.
22. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med. 1999;5:1249-1255.
23. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 1998;392:86-89.
24. Albert ML, Pearce SF, Francisco LM, et al. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med. 1998;188:1359-1368.
25. Inaba K, Turley S, Yamaide F, et al. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J Exp Med. 1998;188:2163-2173.
26. Yamasaki T, Handa H, Yamashita J, et al. Establishment of experimental malignant glioma-specific cytotoxic T lymphocyte clone by T cell growth factor. J Neurosurg. 1984;60:998-1004.
27. Yamasaki T, Handa H, Yamashita J, et al. Specific adoptive immunotherapy with tumor-specific cytotoxic T-lymphocyte clone for murine malignant gliomas. Cancer Res. 1984;44:1776-1783.
28. Yamasaki T, Handa H, Yamashita J, et al. Temporal changes of suppressor T lymphocytes and cytotoxic T lymphocytes in syngeneic murine malignant gliomas. J Neurooncol. 1986;3:353-362.
29. Yamasaki T, Kikuchi H, Yamashita J, et al. Immunoregulatory effects of interleukin 2 and interferon on syngeneic murine malignant glioma-specific cytotoxic T-lymphocytes. Cancer Res. 1988;48:2981-2987.
30. Okada H, Tahara H, Shurin MR, et al. Bone marrow derived dendritic cells pulsed with a tumor specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. Int J Cancer. 1998;78:196-201.
31. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumor immunity. Nat Med. 1995;1:1297-1302.
32. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med. 1992;176:1693-1702.
33. Lohoff M, Ferrick D, Mittrucker HW, et al. Interferon regulatory factor-1 is required for a T helper 1 immune response in vivo. Immunity. 1997;6:681-689.
34. Prevost-Blondel A, Zimmermann C, Stemmer C, et al. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J Immunol. 1998;161:2187-2194.
35. Terakawa S, Fan JH, Kumakura K, et al. Quantitative analysis of exocytosis directly visualized in living chromaffin cells. Neurosci Lett. 1991;123:82-86.
36. Okamoto K, Mizuno M, Nakahara N, et al. Process of apoptosis induced by TNF-α in murine fibroblast Ltk-cell: continuous observation with video enhanced contrast microscopy. Apoptosis. 2002;7:77-86.
37. Giezeman-Smits KM, Okada H, Brissette-Storkus SC, et al. Cytokine gene therapy of gliomas: Induction of reactive CD4+ T cells by interleukin-4 transfected 9L gliosarcoma is essential for protective immunity. Cancer Res. 2000;60:2449-2457.
38. Yoshida J, Mizuno M, Nakahara N, et al. Antitumor effect of an experimental human glioma by adeno-associated virus vector containing the human interferon-beta gene. Jpn J Cancer Res. 2002;93:223-228.
39. Kalinski P, Hilkens CM, Wierenga EA, et al. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. [Review]. Immunol Today. 1999;20:561-567.
40. Vieira PL, de Jong EC, Wierenga EA, et al. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol. 2000;164:4507-4512.
41. Trinchieri G. Interleukin-12 and its role in the generation of TH1 cells. Immunol Today. 1993;14:335-338.
42. Zeh HJ, Hurd S, Storkus WJ, et al. Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancer. J Immunother. 1993;14:155-161.
43. Kalinski P, Schuitemaker JH, Hilkens CM, et al. Final maturation of dendritic cells is associated with impaired responsiveness to IFN-gamma and to bacterial IL-12 inducers: decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells. J Immunol. 1999;162:3231-3236.
44. Dix AR, Brooks WH, Roszman TL, et al. Immune defects observed in patients with primary malignant brain tumors. [Review]. J Neuroimmunol. 1999;100:216-232.
45. Fischer HG, Reichmann G. Brain dendritic cells and macrophages/microglia in central nervous system inflammation. J Immunol. 2001;166:2717-2726.
46. Okada H, Villa LA, Attanucci J, et al. Cytokine gene therapy of gliomas: effective induction of therapeutic immunity to intracranial tumors by peripheral immunization with interleukin-4 transduced glioma cells. Gene Ther. 2001;8:1157-1166.
47. Nehashi K, Yoshida J, Wakabayashi T, et al. Growth inhibition of human glioma cells by superinduced human interferon-beta. Neurol Med Chir (Tokyo). 1995;35:719-722.
48. Hirao M, Onai N, Hiroishi K, et al. CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res. 2000;60:2209-2217.
49. Cella M, Facchetti F, Lanzavecchia A, et al. Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization. Nat Immunol. 2000;1:305-310.
50. Langenkamp A, Messi M, Lanzavecchia A, et al. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol. 2000;1:311-316.
51. Taniguchi T, Takaoka A. A weak signal for strong responses: interferon-alpha/beta revisited. Nat Rev Mol Cell Biol. 2001;2:378-386.
52. Tanaka F, Hashimoto W, Okamura H, et al. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells. Cancer Res. 2000;60:4838-4844.
53. O'Shea JJ, Visconti R. Type I IFNs and regulation of TH1 responses: enigmas both resolved and emerge. Nat Immunol. 2000;1:17-19.
54. Weller M, Fontana A. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain. Brain Res. 1995;21:128-151.
55. Weller RO, Blecham NM, eds. The immunopathology of brain tumours. In: "Tumours of the Brain", Heidelberg, Tokyo, Springer; 1986;19-33.
56. Wiendl H, Mitsdoerffer M, Hofmeister V, et al. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol. 2002;168:4772-4780.
57. Wischhusen J, Jung G, Radovanovic I, et al. Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res. 2002;62:2592-2599.
58. Menetrier-Caux C, Thomachot MC, Alberti L, et al. IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells. Cancer Res. 2001;61:3096-3104.
59. Santambrogio L, Belyanskaya SL, Fischer FR, et al. Developmental plasticity of CNS microglia. Proc Natl Acad Sci USA. 2001;98:6295-6300.
60. Becher B, Prat A, Antel JP. Brain-immune connection: immuno-regulatory properties of CNS-resident cells. GLIA. 2000;29:293-304.
61. Badie B, Schartner JM. Flow cytometric characterization of tumor-associated macrophages in experimental gliomas. Neurosurgery. 2000;46:957-961.
62. Ford AL, Foulcher E, Lemckert FA, et al. Microglia induce CD4 T lymphocyte final effector function and death. J Exp Med. 1996;184:1737-1745.
63. Flugel A, Labeur MS, Grasbon-Frodl EM, et al. Microglia only weakly present glioma antigen to cytotoxic T cells. Int J Dev Neurosci. 1999;17:547-556.
64. Becher B, Blain M, Antel JP. CD40 engagement stimulates IL-12 p70 production by human microglial cells: basis for Th1 polarization in the CNS. J Neuroimmunol 2000;102:44-50.
65. Lin CM, Wang FH, Lee PK. Activated human CD4+ T cells induced by dendritic cell stimulation are most sensitive to transforming growth factor-beta: implications for dendritic cell immunization against cancer. Clin Immunol. 2002;102:96-105.
66. Okada H, Giezeman-Smits KM, Tahara H, et al. Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSV-TK tumor vaccine. Gene Ther. 1999;6:219-226.
67. Heimberger AB, Crotty LE, Archer GE, et al. Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol. 2000;103:16-25.
68. Okada H, Pollack IF, Lieberman F, et al. Gene therapy of malignant gliomas: a pilot study of vaccination with irradiated autologous glioma and dendritic cells admixed with IL-4 transduced fibroblasts to elicit an immune response. Hum Gene Ther. 2001;12:575-595.
69. Nakahara N, Okada H, Witham TF, et al. Combination of stereotactic radiosurgery and cytokine gene-transduced tumor cell vaccination: a new strategy against metastatic brain tumors. J Neurosurg. 2001;95:984-989.